<DOC>
	<DOCNO>NCT01154491</DOCNO>
	<brief_summary>In order evaluate efficacy ferric carboxymaltose + erythropoietin versus ferric carboxymaltose versus placebo reduce percentage patient receive red-cell transfusion perioperative period hip fracture , multicenter , randomize , parallel group , double-blind clinical trial adult patient admit osteoporotic hip fracture design . Required sample size 87 patient per arm ( 87x3 = 261 ) . Primary efficacy variable percentage patient receive red-cell transfusion hospitalization ; secondary end-points : average red-cell pack per patient , haemoglobin 24 h 72h intervention , time hospital discharge 60 day hospital discharge , hospital stay mortality hospital-stay 60 day afterwards . Adverse clinical event side effect assess safety variable . In addition health relate quality life measure inclusion 60 day . A cost-efficacy analysis ( mean incremental cost-efficacy method use primary endpoint patient require transfusion , secondary end-point every patient survive index admission perform ) . The investigator would like demonstrate double benefit : optimize precious resource blood product reduce complication arise use .</brief_summary>
	<brief_title>Efficacy Ferric Carboxymaltose With Without EPO Reducing Red-cell Transfusion Packs Hip Fracture Perioperative Period</brief_title>
	<detailed_description>Three arm treatment : A : ferric carboxymaltose erythropoietin , B : ferric carboxymaltose placebo , arm C : two placebo . Primary objective : reduction red-cell pack need elderly patient osteoporotic hip fracture require surgical intervention perioperative period .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Patients 65 year old . Osteoporotic hip fracture require surgical intervention Haemoglobin level 90120 g/L Signed informed consent form Bone marrow disease could interfere erythropoietic process ( acute chronic myelodysplastic syndrome myeloproliferative disease , and/or infiltration bone marrow due solid lymphatic neoplasm ) Blood coagulation disease currently treat oral anticoagulant and/or heparin therapeutic dos . Documented allergy and/or previous intolerance and/or contraindication erythropoietin use and/or intravenous iron . Patients rheumatoid arthritis and/or another demonstrate origin inflammatory anemia and/or control arterial hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>hip fracture</keyword>
	<keyword>blood substitute</keyword>
	<keyword>blood transfusion</keyword>
	<keyword>intravenous infusion</keyword>
	<keyword>erythropoietin , recombinant</keyword>
	<keyword>frail elderly</keyword>
</DOC>